These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20130920)

  • 21. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
    Mentlein R
    Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.
    Eckerle Mize DL; Salehi M
    Curr Diab Rep; 2013 Jun; 13(3):307-18. PubMed ID: 23479200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New incretin hormonal therapies in humans relevant to diabetic cats.
    Reusch CE; Padrutt I
    Vet Clin North Am Small Anim Pract; 2013 Mar; 43(2):417-33. PubMed ID: 23522180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Deacon CF
    Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.